CD22 low /Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia
2021
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI